Novo Nordisk A/S has initiated a share repurchase program on February 4, 2026, with a budget of DKK 15 billion over 12 months, repurchasing 9.16 million shares for DKK 2.40 billion as of March 27, 2026, averaging DKK 261.91 per share. This filing is significant and conveys a positive sentiment for investors.